Literature DB >> 26628846

Intestinal FXR: A New Therapeutic Target for Nonalcoholic Fatty Liver Disease.

Sawan Bopanna1.   

Abstract

Entities:  

Year:  2015        PMID： 26628846      PMCID： PMC4632102          DOI： 10.1016/j.jceh.2015.08.006

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


× No keyword cloud information.
  13 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 2.  Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.

Authors:  Herbert Tilg; Alexander R Moschen
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

3.  The role of the gut microbiota in nonalcoholic fatty liver disease.

Authors:  Ahmed Abu-Shanab; Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

Review 4.  Nuclear receptor regulation of lipid metabolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases.

Authors:  John Y L Chiang
Journal:  Curr Opin Investig Drugs       Date:  2005-10

5.  Bile acids: natural ligands for an orphan nuclear receptor.

Authors:  D J Parks; S G Blanchard; R K Bledsoe; G Chandra; T G Consler; S A Kliewer; J B Stimmel; T M Willson; A M Zavacki; D D Moore; J M Lehmann
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

Review 6.  Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.

Authors:  Geoffrey Porez; Janne Prawitt; Barbara Gross; Bart Staels
Journal:  J Lipid Res       Date:  2012-05-01       Impact factor: 5.922

Review 7.  Nonalcoholic fatty liver disease: from steatosis to cirrhosis.

Authors:  Geoffrey C Farrell; Claire Z Larter
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

8.  Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

Authors:  Changtao Jiang; Cen Xie; Fei Li; Limin Zhang; Robert G Nichols; Kristopher W Krausz; Jingwei Cai; Yunpeng Qi; Zhong-Ze Fang; Shogo Takahashi; Naoki Tanaka; Dhimant Desai; Shantu G Amin; Istvan Albert; Andrew D Patterson; Frank J Gonzalez
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

Review 9.  Targeting bile-acid signalling for metabolic diseases.

Authors:  Charles Thomas; Roberto Pellicciari; Mark Pruzanski; Johan Auwerx; Kristina Schoonjans
Journal:  Nat Rev Drug Discov       Date:  2008-08       Impact factor: 84.694

10.  Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation.

Authors:  Nyingi Kemmer; Guy W Neff; Edson Franco; Hussein Osman-Mohammed; John Leone; Erin Parkinson; Elizabeth Cece; Angel Alsina
Journal:  Transplantation       Date:  2013-11-27       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.